Biocytogen Pharmaceuticals (Beijing) Co., has announced the opening of the Biocytogen Europe Innovation Centre (BEIC) in Heidelberg, Germany.

Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony.

Dr. Vivian Tian, Head of BEIC, hosted the event, and introduced Biocytogen's history, pipeline, and technology platforms, as well as the strategic positioning of BEIC. 

Germany has long been considered the "world's pharmacy" — home to Bayer, Merck and Boehringer Ingelheim – with its strength most recently highlighted by the success of the COVID-19 mRNA vaccine. In particular, Heidelberg is a scientific hub in Germany with several renowned institutions.

This environment of innovation, world-class facilities and top scientific talent positions the BEIC to form new collaborations with European partners to develop and commercialize Biocytogen's clinical and preclinical assets, as well as to further strengthen local partnerships to discover novel antibody drugs emerging from Biocytogen's Project Integrum, a large-scale initiative to develop antibodies with first-in-class and/or best-in-class potential to over 1000 druggable targets.